ADAM-15 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAM-15 (UniProt Q13444), expressed in HEK293 cells. Active metalloproteinase with gelatinolytic and collagenolytic activity; used in substrate cleavage assays, inhibitor profiling, and antibody validation.
Expression system
HEK293
Cat. #
REC-ADAM15

In stock

SKU
REC-ADAM15
$498.00

Target Overview

ADAM-15 (Disintegrin and metalloproteinase domain-containing protein 15; UniProt Q13444) is an 863-amino-acid type I transmembrane metalloproteinase encoded by the ADAM15 gene. It belongs to the ADAM (A Disintegrin And Metalloproteinase) family, characterised by a pro-domain, a zinc-dependent metalloproteinase domain, a disintegrin domain, and a cysteine-rich region. ADAM-15 carries a functional RGD motif within its disintegrin domain — a feature that distinguishes it from most other ADAM family members and enables direct integrin binding. This recombinant is produced in HEK293 mammalian cells, providing the post-translational processing and glycosylation patterns appropriate for an enzyme that undergoes proteolytic activation of its pro-domain. The full-length human sequence spans 863 residues; researchers should consult the current lot documentation for the precise expressed region and tag configuration of this preparation. In substrate cleavage studies, the recombinant is active against gelatin and collagen substrates, making it suitable for fluorometric and gel-based protease activity assays. Its documented ability to cleave E-cadherin in a growth-factor-deprivation context provides a defined substrate system for mechanistic studies. The disintegrin domain supports integrin-binding competition assays and SPR-based biophysical characterisation. For inhibitor profiling, the recombinant is compatible with standard metalloproteinase inhibitor panels and can be used to establish IC50 values against hydroxamate-based or other zinc-chelating compound series. Researchers validating anti-ADAM15 antibodies can use this recombinant as a positive-control antigen. It is supplied alongside Triple Point Biologics' matched anti-ADAM15 antibody (SKU: RP-ADAM15), which has been validated for Western blot against human ADAM-15. Triple Point Biologics has produced proteinase and inhibitor antibody reagents since 1994, and the RP-ADAM15 antibody is designed to work in conjunction with this recombinant standard.

Background

ADAM-15 (Metargidin; MDC-15) is a multidomain metalloproteinase with documented gelatinolytic and collagenolytic activity that positions it at the intersection of extracellular matrix remodelling, cell adhesion, and integrin signalling. Functionally, it modulates beta-1 integrin-mediated cell adhesion and migration in airway smooth muscle cells, suppresses fibronectin-directed cell motility through ERK1/2 inactivation-driven changes in alpha-v/beta-1 integrin surface expression, and participates in glomerular cell migration — making it a protein of interest across multiple tissue and disease contexts in basic research. The enzyme's documented substrates include E-cadherin, cleaved in response to growth factor deprivation, and the extracellular matrix components gelatin and collagen. Its RGD-containing disintegrin domain provides an additional layer of biological activity through direct integrin engagement, a property exploited in cell-adhesion competition assays and structural studies. ADAM-15 has been studied as a research target across several oncology contexts. Junhui X et al. (2026) demonstrated that ADAM-15 promotes hepatocellular carcinoma progression and metastasis through activation of the JNK/p38 MAPK pathway, providing a mechanistic basis for its role in tumour cell behaviour (PMID: 41986445). Independent pan-cancer analyses by Guo W et al. (2026) identified ADAM-15 expression as a prognostic variable across multiple tumour types, with validation in hepatocellular carcinoma and colon adenocarcinoma cohorts (PMID: 41630479). In breast cancer research, ADAM-15 transcript levels have been incorporated into extracellular matrix protease signatures evaluated by machine learning approaches for survival prediction (Babas R et al., 2026; PMID: 42192859), and Mendelian randomisation analyses have flagged it among druggable proteins in the chronotype–breast cancer association (Luo S et al., 2026; PMID: 42323475). In colorectal cancer, comprehensive expression analyses have characterised ADAM15 alongside other ADAM family members as a candidate biomarker (Romanowicz A et al., 2026; PMID: 41976350). Beyond oncology, published work has implicated ADAM-15 in wound healing, pathological neovascularisation, cartilage remodelling, and sperm maturation/acrosome reactions, reflecting the breadth of biological contexts in which recombinant ADAM-15 has utility as a biochemical tool. This recombinant is intended strictly for in vitro research use. Researchers requiring antibody co-validation should pair this protein with the matched Triple Point Biologics anti-ADAM15 antibody (RP-ADAM15).

Applications

  • Fluorometric gelatinolytic activity assay to confirm recombinant enzyme activity using DQ-gelatin or FITC-gelatin substrates
  • Collagenolytic substrate cleavage assay using fibrillar collagen to characterise metalloproteinase domain function
  • Metalloproteinase inhibitor IC50 determination against hydroxamate-based or zinc-chelating compound libraries
  • E-cadherin ectodomain cleavage assay as a defined physiological substrate system for mechanistic or compound-screening studies
  • Western blot positive-control antigen for validation of anti-ADAM15 antibodies, including TPB RP-ADAM15
  • Integrin-binding competition assay exploiting the RGD-containing disintegrin domain to study alpha-v/beta-1 integrin interactions
  • Surface plasmon resonance (SPR) or bio-layer interferometry (BLI) binding kinetics with candidate inhibitors or integrin ectodomains
  • Immunogen or capture antigen in ELISA development or antibody epitope-mapping studies

References

  1. Luo S et al. Identifying druggable proteins of the association of chronotype on breast cancer using Mendelian randomization. Commun Med (Lond). 2026. doi:10.1038/s43856-026-01731-2. PMID: 42323475.
  2. Babas R et al. Integrative Survival Prediction in Breast Cancer Using Extracellular Matrix Protease Transcript Signatures and Clinical Variables: A Machine Learning Approach. Cancers (Basel). 2026. doi:10.3390/cancers18101497. PMID: 42192859.
  3. Junhui X. ADAM15 promotes the progression and metastasis of hepatocellular carcinoma by activating the JNK/p38 pathway. Sci Rep. 2026. doi:10.1038/s41598-026-48902-8. PMID: 41986445.
  4. Romanowicz A et al. The Potential of A Disintegrin and Metalloproteinase (ADAM) Proteins as Clinically Relevant Biomarkers in Colorectal Cancer: A Comprehensive Analysis. Cancers (Basel). 2026. doi:10.3390/cancers18071127. PMID: 41976350.
  5. Guo W et al. ADAM15 Is a Potential Biomarker for Pan-Cancer Prognosis and Immunotherapy: Validation in HCC and COAD. IUBMB Life. 2026. doi:10.1002/iub.70086. PMID: 41630479.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type I transmembrane; cell surface; Golgi → endosomes

Frequently Asked Questions

What molecular weight band should I expect for recombinant ADAM-15 on SDS-PAGE or Western blot?

The full-length human ADAM-15 polypeptide encodes 863 amino acids, giving a predicted unglycosylated MW of ~98 kDa. Because this preparation is produced in HEK293 cells with native-like N-glycosylation, the observed band on reducing SDS-PAGE typically runs at 100–115 kDa depending on glycan load and the expressed region in your specific lot. Always confirm the precise expressed region and tag contribution from your current lot datasheet. Under non-reducing conditions, apparent MW may shift further due to intramolecular disulfide architecture in the cysteine-rich domain.

Is the recombinant ADAM-15 the pro-domain form or the mature processed form?

ADAM-15 undergoes autocatalytic or furin-mediated removal of its N-terminal pro-domain as part of activation. The HEK293 expression system used here supports endogenous proprotein convertase activity, so a significant proportion of the preparation is in the mature, pro-domain-cleaved form. However, a mixture of precursor and processed species is common with ADAM family members. Your lot datasheet will indicate the dominant species observed by SDS-PAGE. If you need to confirm activation state, the metalloproteinase inhibitor EDTA (5–10 mM) will suppress any residual auto-processing during analysis.

What substrates can I use to measure ADAM-15 metalloproteinase activity in a fluorescent assay?

ADAM-15 cleaves peptide substrates containing the core sequence recognized by meltrin-family sheddases. Internally quenched fluorescent (IQF) substrates such as Mca-KPLGL-Dpa-AR-NH2 or the generic ADAM substrate Mca-PLAQAV-Dpa-NH2 are commonly used starting points. Assay in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2 (matching the storage buffer) at 37°C. A starting enzyme concentration of 50–200 nM with substrate at 10–20 µM provides a linear initial velocity window. Include 10 mM EDTA or 10 µM GM6001 as a negative control to confirm metal-dependent activity.

What buffer conditions are optimal for ADAM-15 activity assays and does the storage buffer interfere?

The storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — is directly compatible with standard ADAM-15 activity assays. Dilute the enzyme at least 1:10 into assay buffer to bring glycerol to ≤1%, which minimizes viscosity effects on fluorescence readings. Maintain 1–5 mM CaCl2 in the final assay; calcium chelation by residual EDTA from other reagents is a common cause of activity loss. Avoid Zn²⁺-chelating buffers (e.g., HEPES with trace EDTA) without supplementing ZnCl2 at 1–10 µM to support the catalytic zinc center.

What starting concentration of recombinant ADAM-15 should I use for an inhibitor IC50 experiment?

For IC50 determination, use 25–100 nM recombinant ADAM-15 with your IQF substrate at a concentration at or below the apparent Km (typically 10–20 µM for generic ADAM substrates). Keeping enzyme well below substrate concentration ensures you are measuring inhibitor competition under conditions approximating Cheng-Prusoff validity. Pre-incubate enzyme with inhibitor for 15–30 minutes at room temperature before adding substrate to allow equilibrium binding, particularly for slow-on inhibitors like hydroxamic acid-based compounds. Run each IC50 curve with a GM6001 reference standard to confirm assay consistency between experiments and lots.

Can I use recombinant ADAM-15 as a positive control for Western blot with the matched TPB antibody RP-ADAM15?

Yes — this is the most straightforward use case. RP-ADAM15 (/anti-adam-15-rabbit-polyclonal-antibody) is produced in the same laboratory against ADAM-15 antigen and is guaranteed compatible with this recombinant for Western blot. Load 20–50 ng of recombinant ADAM-15 per lane on a 4–12% Bis-Tris gel; expect a band at 100–115 kDa. This loading is sufficient for clear detection with RP-ADAM15 at standard dilutions without saturating the signal, leaving room to compare against endogenous ADAM-15 in your cell lysate lanes on the same membrane.

How much recombinant ADAM-15 should I load for a Western blot positive control and what dilution of RP-ADAM15 antibody should I use?

Load 20–50 ng of recombinant ADAM-15 per lane. At this quantity, RP-ADAM15 (SKU: RP-ADAM15) used at 1:500–1:2000 in 5% non-fat milk or BSA in TBST will produce a clean band at 100–115 kDa within standard ECL exposure times (1–5 minutes). If you are co-detecting endogenous ADAM-15 in tissue lysates — which express the protein at lower levels — titrate the antibody toward 1:500 and increase lysate loading to 20–30 µg total protein. The recombinant positive control lane anchors band identity and confirms antibody lot-to-lot consistency.

How should I handle, dilute, and store recombinant ADAM-15 to maintain activity over time?

Recombinant ADAM-15 is supplied as a sterile solution in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2. Upon receipt, aliquot into single-use volumes before freezing at -20°C; repeated freeze-thaw cycles accelerate aggregation and loss of metalloproteinase activity. For working dilutions, use the storage buffer or a compatible assay buffer containing 0.1% BSA as a carrier when diluting below ~100 ng/µL to prevent adsorptive losses to tube walls. Diluted enzyme should be used within 4–8 hours on ice. Do not store diluted working stocks.

Validation imagery coming soon

Western blot validation figures for REC-ADAM15 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →